Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fludarabine Induction and Alemtuzumab Consolidation in Untreated CLL
NCT00004857Phase 2Completed
- Sponsor
- Cancer and Leukemia Group B
- Start
- Jan 2000
- Primary completion
- Mar 2003
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of alemtuzumab in chronic lymphocytic leukemia (CLL), sponsored by Cancer and Leukemia Group B. Started Jan 2000; status: completed.
02
Drugs
alemtuzumab
03
Conditions
chronic lymphocytic leukemia (CLL)
Beyond the preview
Go deeper on NCT00004857.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00004857.